Debiopharm Group, Pfizer deal

Pfizer and Debiopharm will co-develop Pfizer's tremelimumab to treat advanced melanoma. Debiopharm is responsible for conducting a Phase III trial of the mAb against CTLA-4 (CD152), and Pfizer will ...